Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 147 participants.

Also called NCT02620384

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 147 participants (enrolled count) (from the registry)
Sponsor
Aultman Health Foundation (from the registry)
Registry
  • NCT NCT02620384
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02620384. Randomized; triple masking; primary purpose treatment. Start 2015-10-01 (actual); primary completion 2017-11-29 (actual). Results posted on 2019-02-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.
Acronym
MELT-HF
Condition
Acute Decompensated Heart Failure
Intervention (Drug)
Experimental: Placebo
Intervention (Drug)
Experimental: Metolazone
Lead sponsor
Aultman Health Foundation (class: other)

Record details

Record id
cardio:ct-nct02620384
Content hash
6660b929811ec97811c58922ef85ed24db39220c8f7680d4571be01056b749bb